Research programme: opioid antagonist implant - Opiant

Drug Profile

Research programme: opioid antagonist implant - Opiant

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Opiant Pharmaceuticals
  • Class Drug withdrawal therapies; Morphinans; Opioid analgesics
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Opioid abuse

Most Recent Events

  • 02 Oct 2017 Titan Pharmaceuticals and Opiant Pharmaceuticals agree to develop opioid antagonist implant
  • 02 Oct 2017 Early research in Opioid abuse in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top